Navigating the Complexities of Adding Rare Disease Products to Your Company’s Portfolio

Rare disease products, biopharmaceutical development, commercialization, market access, patient identification, payer contract strategy, value-based contracting, regulatory incentives, emerging technology.

RYBREVANT: A Breakthrough in Lung Cancer Treatment

RYBREVANT, lung cancer, EGFR mutations, subcutaneous administration, intravenous administration, infusion-related reactions, survival rate, non-small cell lung cancer (NSCLC)